Mirum Pharmaceuticals, Inc. (MIRM)
NASDAQ: MIRM · Real-Time Price · USD
98.14
-4.10 (-4.01%)
Aug 20, 2026, 12:44 PM EDT - Market open
Mirum Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 618.07 | 521.31 | 336.89 | 186.37 | 77.06 | 19.14 | |
Revenue Growth | 44.02% | 54.74% | 80.76% | 141.85% | 302.67% | - |
Cost of Revenue | 112.95 | 100.24 | 81.64 | 47.04 | 12.37 | 1.9 |
Gross Profit | 505.11 | 421.07 | 255.25 | 139.34 | 64.69 | 17.24 |
Selling, General & Admin | 313.84 | 257.03 | 202.22 | 145.88 | 89.07 | 59.22 |
Research & Development | 287.51 | 186.18 | 140.63 | 102.61 | 106.84 | 131.43 |
Operating Expenses | 601.34 | 443.21 | 342.85 | 248.49 | 195.91 | 190.65 |
Operating Income | -96.23 | -22.14 | -87.61 | -109.15 | -131.22 | -173.41 |
Interest Expense | -13.44 | -14.39 | -14.31 | -15.11 | -15.98 | -17.59 |
Interest & Investment Income | 13.92 | 12.73 | 13.79 | 13.74 | 3.86 | 0.37 |
Currency Exchange Gain (Loss) | -1.1 | 0.7 | 1.2 | -1.8 | - | - |
Other Non Operating Income (Expenses) | -22.96 | 1.67 | 0.01 | -1.02 | 1.27 | 106.69 |
EBT Excluding Unusual Items | -119.8 | -21.43 | -86.91 | -113.35 | -142.07 | -83.95 |
Other Unusual Items | - | - | - | -49.08 | - | - |
Pretax Income | -857.54 | -21.43 | -86.91 | -162.42 | -142.07 | -83.95 |
Income Tax Expense | 2.67 | 1.94 | 1.03 | 0.99 | -6.41 | 0.04 |
Net Income | -860.21 | -23.36 | -87.94 | -163.42 | -135.67 | -83.99 |
Net Income to Common | -860.21 | -23.36 | -87.94 | -163.42 | -135.67 | -83.99 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 56 | 50 | 48 | 41 | 34 | 30 |
Shares Outstanding (Diluted) | 56 | 50 | 48 | 41 | 34 | 30 |
Shares Change | 15.36% | 5.63% | 16.23% | 20.31% | 12.07% | 20.08% |
EPS (Basic) | -15.33 | -0.47 | -1.85 | -4.00 | -4.01 | -2.77 |
EPS (Diluted) | -15.34 | -0.47 | -1.85 | -4.00 | -4.02 | -2.77 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -228.74 | 54.87 | 9.33 | -71.05 | -120.41 | -132.78 |
Free Cash Flow Per Share | -4.08 | 1.09 | 0.20 | -1.74 | -3.54 | -4.38 |
Gross Margin | 81.73% | 80.77% | 75.77% | 74.76% | 83.94% | 90.06% |
Operating Margin | -15.57% | -4.25% | -26.00% | -58.57% | -170.28% | -906.12% |
Profit Margin | -139.18% | -4.48% | -26.10% | -87.68% | -176.05% | -438.86% |
Free Cash Flow Margin | -37.01% | 10.53% | 2.77% | -38.12% | -156.26% | -693.81% |
EBITDA | -70.28 | 2.11 | -63.98 | -98.33 | -127.98 | -172.82 |
EBITDA Margin | -11.37% | 0.40% | -18.99% | -52.76% | -166.08% | - |
D&A For EBITDA | 25.95 | 24.24 | 23.63 | 10.83 | 3.24 | 0.6 |
EBIT | -96.23 | -22.14 | -87.61 | -109.15 | -131.22 | -173.41 |
EBIT Margin | -15.57% | -4.25% | -26.00% | -58.57% | -170.28% | - |
Revenue as Reported | 521.31 | 521.31 | 336.89 | 186.37 | 77.06 | 19.14 |
Advertising Expenses | - | 10.9 | 11.5 | 6.3 | 4 | 9.2 |